June 21, 2018
Immunocompetent Murine Models for Immunotherapy Assessment
Immunocompetent models are necessary for the preclinical assessment of novel immunotherapies, but multiple murine model platforms are available for the evaluation of cross reactive and surrogate agents. Here we look at syngeneics, GEMM, and murine tumor homograft models and how to choose the best model for your immuno-oncology study.
LEARN MORE
June 12, 2018
Leveraging PDX Models for In Vitro and Ex Vivo Assays
Patient-derived xenografts (PDX) are the most predictive and translational xenograft models available for preclinical ...
LEARN MORE
June 5, 2018
PDX and Personalized Medicine
We discussed patient-derived xenografts (PDX) previously, from how to establish the models to when to add them to ...
LEARN MORE
May 31, 2018
Predictive Immuno-Oncology Studies with Humanized PDX
Patient-derived xenograft (PDX) models are typically immunodeficient and inappropriate for most immuno-oncology (I/O) ...
LEARN MORE
May 29, 2018
Webinar FAQ: PDX Models in Drug Discovery Assays
Patient-derived xenografts (PDX) are the most predictive and translational preclinical xenograft models available for ...
LEARN MORE
May 24, 2018
Webinar FAQ: Humanized PDX Models in Immuno-Oncology
Patient-derived xenografts (PDX) support highly translational preclinical oncology research, but were historically ...
LEARN MORE
May 22, 2018
Immuno-Oncology and the Microbiome at AACR 2018
CrownBio presented thirteen posters at AACR 2018, sharing our latest internal research into patient derived xenografts, humanized models, murine immuno-oncology models, and in vitro/ex vivo platforms. One particularly interesting poster we presented explored gut microbiota modulation following treatment with a PD-1 inhibitor, with potential implications for ...
LEARN MORE
May 17, 2018
Genetically Engineered or Syngeneic Mouse Models?
Mouse models are a mainstay of preclinical cancer research, and immunocompetent model use is rising with continued ...
LEARN MORE
May 15, 2018
Murine Homograft Tumor Models at AACR 2018
We presented a wide range of immuno-oncology model data at AACR 2018, with three of our thirteen posters covering our ...
LEARN MORE
May 10, 2018
In Vitro and Ex Vivo Assay Platforms at AACR 2018
We presented a wide range of oncology modelling capabilities at AACR 2018, spanning the breadth of preclinical ...
LEARN MORE
May 8, 2018
Latest Data on PDX Models at AACR 2018
We presented the latest data on our PDX models at this year’s AACR Annual Meeting in Chicago, with new studies on DLBCL models with diverse genotypes for BTK inhibitor testing, comparison of WES and RNAseq in PDX models, and on using PDX as a new model system to investigate the tumor microenvironment (TME).
LEARN MORE
May 3, 2018
Humanized Mouse Model Posters at AACR 2018
CrownBio presented thirteen posters at AACR 2018, showcasing a wide range of our oncology and immuno-oncology ...
LEARN MORE
April 27, 2018
Understanding Cancer Progression and Metastasis
“Cancer progression” is the process by which this disease goes from bad to worse. Molecularly, the course of cancer ...
LEARN MORE
April 20, 2018
Preclinical Assessment of Osimertinib for NSCLC with EGFR Exon 20 Insertions
NSCLC patients with EGFR exon 20 insertions lack treatment options, partly due to a lack of patient genotype-relevant ...
LEARN MORE
April 13, 2018
The Establishment and Characterization of PDX Models
Patient-derived xenograft models (PDX) support more predictive, clinically-representative in vivo oncology studies than ...
LEARN MORE
